Travere Therapeutics Inc TVTX.OQ TVTX.O is expected to show a rise in quarterly revenue when it reports results on February 20 for the period ending December 31 2024
The San Diego California-based company is expected to report a 62.8% increase in revenue to $73.335 million from $45.06 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
LSEG's mean analyst estimate for Travere Therapeutics Inc is for a loss of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Travere Therapeutics Inc is $31.00, above its last closing price of $22.91.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.69 | -0.68 | -0.70 | Missed | -3 |
Jun. 30 2024 | -0.87 | -0.86 | -0.91 | Missed | -5.7 |
Mar. 31 2024 | -0.97 | -0.99 | -1.76 | Missed | -77.6 |
Dec. 31 2023 | -1.32 | -1.27 | -1.03 | Beat | 19.1 |
Sep. 30 2023 | -0.02 | -0.14 | -1.17 | Missed | -719.7 |
Jun. 30 2023 | -1.20 | -1.14 | -1.13 | Beat | 1 |
Mar. 31 2023 | -1.16 | -1.17 | -1.27 | Missed | -8.5 |
Dec. 31 2022 | -1.08 | -1.07 | -1.03 | Beat | 4.1 |
This summary was machine generated February 18 at 21:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。